Amphastar Pharmaceuticals operates primarily in the United States, with additional manufacturing and research facilities in China and France. The company's portfolio includes over 25 prescription pharmaceutical products and the over-the-counter asthma inhaler Primatene MIST. Its key offerings span critical care and respiratory therapies, featuring products such as BAQSIMI (a glucagon nasal powder), epinephrine, naloxone, and lidocaine. Amphastar also manufactures active pharmaceutical ingredients (APIs), including recombinant human insulin and porcine insulin. By focusing on complex delivery systems like pre-filled syringes and inhalation aerosols, the company maintains a competitive edge in niche markets with limited competition.
